BVS Stock Analysis: Buy, Sell, or Hold?
BVS - Bioventus Inc. Class A Common Stock
$8.97
-0.18 (-1.97%)
▼
5d:
-3.13%
30d:
+5.9%
90d:
+20.56%
BUY
MODERATE Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 05, 2026
Get Alerted When BVS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: BVS shows positive signals but monitor for confirmation. Market pricing in 0.8% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: BVS shows positive signals but monitor for confirmation. Market pricing in 0.8% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$14.13
Based on 10.2% avg growth
INTRINSIC VALUE TODAY
$8.78
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BVS is currently trading at $8.97, which is considered slightly high relative to its 30-day fair value range of $8.65 to $9.08. The stock's valuation (Forward PE: 10.2) is in line with its historical norms (10.0). At these levels, the market is pricing in 0.8% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, BVS is in a strong uptrend. Immediate support is located at $8.46, while resistance sits at $9.39.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $14.80 (+65.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, BVS is in a strong uptrend. Immediate support is located at $8.46, while resistance sits at $9.39.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $14.80 (+65.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Fair Price Range
$8.65 -
$9.08
Company Quality Score
60/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
66.2%
All Signals
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 65.0% below Wall St target ($14.80)
- NEUTRAL: Market pricing in 0.8% annual earnings growth - fairly valued
Fair Price Analysis
30-Day Fair Range
$8.65 -
$9.08
Current vs Fair Value
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$8.46
Resistance Level
$9.39
Current Trend
Strong Uptrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.25
Wall Street Target
$14.80
(+65.0%)
Revenue Growth (YoY)
2.8%
Profit Margin
4.0%
Valuation Premium vs History
+0.8% premium
PE vs Historical
10.3 vs 10.0
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.8%
(market-implied from PE analysis)
1-Year Target
$9.04
(+1%)
2-Year Target
$9.11
(+2%)
3-Year Target
$9.19
(+2%)
3-Yr Target (if PE normalizes)
(PE: 10→10)
PE COMPRESSION
$8.96
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.6, Growth: 16.3%)
$28.30
(+216%)
Base:
(SPY PE: 10.3, Growth: 16.3%)
$14.10
(+57%)
Bear:
(PE: 8.7, Growth: 16.3%)
$11.99
(+34%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (26x PE), but valuation improves significantly next year (10x PE) as earnings recover.
Trailing PE: 26.18 | Current EPS (TTM): $0.33
Bull Case
$19.01
(+111%)
Analyst growth 100.0%, PE expands to 28.8
Base Case
$17.28
(+92%)
Market implied 100.0%, PE stable at 26.2
Bear Case
$5.88
(-35%)
Severe decline -20.0%, PE contracts to 22.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: April 02, 2026 8:55 PM ET
Data refreshes hourly during market hours. Next update: 9:55 PM
Data refreshes hourly during market hours. Next update: 9:55 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BVS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Michelle Mcmurry-Heath
SELL
12000 shares
2026-03-11
Guy P Nohra
SELL
10000 shares
2025-12-04
Michelle Mcmurry-Heath
SELL
17701 shares
2025-11-07
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$102 | 60 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$424 | 61 BUY |
|
ABT
Abbott Laboratories |
BUY
28 analysts |
$133 | 59 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
26 analysts |
$86 | 47 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
23 analysts |
$354 | 52 HOLD |
